Download MendeleyDiscovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Smith, C.R., Chen, D., Christensen, J.G., Coulombe, R., Fethiere, J., Gunn, R.J., Hollander, J., Jones, B., Ketcham, J.M., Khare, S., Kuehler, J., Lawson, J.D., Marx, M.A., Olson, P., Pearson, K.E., Ren, C., Tsagris, D., Ulaganathan, T., Van't Veer, I., Wang, X., Ivetac, A.(2024) J Med Chem 67: 774-781
- PubMed: 38156904
- DOI: https://doi.org/10.1021/acs.jmedchem.3c02140
- Primary Citation of Related Structures:
8T5G, 8T5M, 8T5R, 8UC9, 8UF2, 8UH0 - PubMed Abstract:
SOS1 and SOS2 are guanine nucleotide exchange factors that mediate RTK-stimulated RAS activation. Selective SOS1:KRAS PPI inhibitors are currently under clinical investigation, whereas there are no reports to date of SOS2:KRAS PPI inhibitors. SOS2 activity is implicated in MAPK rebound when divergent SOS1 mutant cell lines are treated with the SOS1 inhibitor BI-3406; therefore, SOS2:KRAS inhibitors are of therapeutic interest. In this report, we detail a fragment-based screening strategy to identify X-ray cocrystal structures of five diverse fragment hits bound to SOS2.
Organizational Affiliation:
Mirati Therapeutics, San Diego, California 92130, United States.
